Close
Close
Emerging Treatments for Acute Myelogenous Leukemia
401 views
2.4
2.4 from 10 votes

Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapyradiation therapybone marrow transplant and/or other drug therapy.

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses treatment options for acute myelogenous leukemia (AML), which comprise a variety of chemotherapy regimens and stem cell transplantation. Current standard chemotherapy regimens cure only a minority of patients with AML. As a result, all patients should be evaluated for entry into well-designed clinical trials. Actinium's Iomab-B is intended to be an induction and conditioning agent prior to a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT) with an initial indication in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above.

Learn more about:

Access Programs

2.4
2.4 from 10 votes
Free Newsletter
Find a Clinical Trial
Related Videos